Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Vimentin 3 Expression in Prostate Cancer Cells

BARBARA KÖDITZ, ANDREAS STOG, HEIKE GÖBEL, ISABELL HEIDEGGER, JOCHEN FRIES, AXEL HEIDENREICH and MELANIE VON BRANDENSTEIN
Anticancer Research January 2021, 41 (1) 169-174; DOI: https://doi.org/10.21873/anticanres.14762
BARBARA KÖDITZ
1University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Urology, Cologne, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: barbara.koeditz@uk-koeln.de
ANDREAS STOG
1University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Urology, Cologne, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HEIKE GÖBEL
2Department of Pathology University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ISABELL HEIDEGGER
3University Hospital of Innsbruck, Department of Urology, Innsbruck, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOCHEN FRIES
1University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Urology, Cologne, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AXEL HEIDENREICH
1University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Urology, Cologne, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MELANIE VON BRANDENSTEIN
1University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Urology, Cologne, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Vimentin3 (Vim3) was recently described as a tumour marker for the direct discrimination between benign and malignant kidney tumours. Here, we examined its expression in prostate cancer (PCa) cell lines and the regulation of its expression by endothelin receptors. Materials and Methods: Prostate cancer cell lines (PC3, DU145, LNCap) were incubated with endothelin 1 (ET-1), BQ123 [endothelin A receptor (ETAR) antagonist], BQ788 [endothelin B receptor (ETBR) antagonist], BQ123+ET-1, BQ788+ET-1 for 24 h and a scratch assay was performed. Cell extracts were analysed by western blotting and qRT-PCR. Results: ET-1 induced Vim3 overexpression. Blocking the ETBR in the different prostate cancer cell lines yielded a higher migration rate, whereby Vim3 expression was significantly increased. Conclusion: Vim3 concentration increases in cell lines without a functional ETBR and may be used as a marker for PCas where ETBR is frequently methylated.

Key Words:
  • Prostate cancer
  • Vimentin 3
  • Endothelin-1
  • Received October 28, 2020.
  • Revision received November 19, 2020.
  • Accepted November 20, 2020.
  • Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (1)
Anticancer Research
Vol. 41, Issue 1
January 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vimentin 3 Expression in Prostate Cancer Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Vimentin 3 Expression in Prostate Cancer Cells
BARBARA KÖDITZ, ANDREAS STOG, HEIKE GÖBEL, ISABELL HEIDEGGER, JOCHEN FRIES, AXEL HEIDENREICH, MELANIE VON BRANDENSTEIN
Anticancer Research Jan 2021, 41 (1) 169-174; DOI: 10.21873/anticanres.14762

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Vimentin 3 Expression in Prostate Cancer Cells
BARBARA KÖDITZ, ANDREAS STOG, HEIKE GÖBEL, ISABELL HEIDEGGER, JOCHEN FRIES, AXEL HEIDENREICH, MELANIE VON BRANDENSTEIN
Anticancer Research Jan 2021, 41 (1) 169-174; DOI: 10.21873/anticanres.14762
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer
  • Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma
  • Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance via Inhibition of RAF Dimerization in PLX4032-resistant Melanoma
Show more Experimental Studies

Similar Articles

Keywords

  • Prostate cancer
  • Vimentin 3
  • Endothelin-1
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire